Black Diamond Therapeutics, Inc. (BDTX) on Decifer

Decifer ranks BDTX number 273 of 274 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 15% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is not growing right now and profits grew 131% over the past year.
• It keeps a high share of every sale as profit.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• It keeps issuing a lot of new shares, which dilutes its owners and it returns cash to shareholders.
• Profits grew 131% and returns run 15%, but flat revenue, heavy share issuance, no growth role, and momentum of 0 out of 35 below trend leave nothing to buy now.

The current read

The evidence on BDTX lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full BDTX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.